Q&A

Ensuring Success In Early Biopharmaceutical Formulation Development

Source: Catalent
GettyImages-1346675584-team-lab-research-development

Biopharmaceuticals tend to be highly unstable. A pilot formulation study at the early drug substance development stage can make things considerably easier at the manufacturing stage, according to Yunsong (Frank) Li, director of process development at Catalent Biologics, in this interview.

access the Q&A!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Catalent